Testing medicines to prevent lung cancer requires treating many thousands of high-risk individuals and then waiting five, 10 or 15 years to discover which of them develop cancer and which, if any, experience survival benefit from the treatment. A new study proposes a possible point on the way to benefit, which if validated, could dramatically reduce the number of patients needed and time required to test drugs for lung cancer prevention.